CD99, which is highly expressed in T-acute lymphoblastic leukemia (T-ALL), could be an effective target for antibody-based treatment. In this study, researchers used a monoclonal antibody against CD99 called mAb MT99/3, which triggers the death of cancerous T-ALL cells without affecting healthy cells. The study also revealed that this antibody causes the activation of several genes related to cell death. Additionally, the researchers discovered a new part of CD99 that the antibody targets, which hasn’t been reported before. This discovery could lead to the development of a new treatment for T-ALL, making mAb MT99/3 a promising candidate for future therapies.
Funding
The Office of the Permanent Secretary, the Ministry of Higher Education, Science, Research and Innovation (OPS MHESI); Thailand Science Research and Innovation (TSRI) and Chiang Mai University. (grant numbers RGNS 64—068)
The Distinguished Research Professor Grant of the National Research Council of Thailand (grant numbers NRCT808/2563)
Original Paper
Title of original paper: Transcriptome Analysis Reveals the Induction of Apoptosis-Related Genes by a Monoclonal Antibody against a New Epitope of CD99 on T-Acute Lymphoblastic Leukemia
Journal: Antibodies (Basel).
DOI: https://doi.org/10.3390/antib13020042
Correspondence
- Watchara Kasinrerk